Trends in Molecular Medicine
ReviewHeterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy
Section snippets
Basic features of MS lesions
The pathology of MS is distinguished from that of other inflammatory diseases of the nervous system by the presence of large, multifocal, demyelinated plaques with reactive glial scar formation 1, 2. This demyelinating process is accompanied by an inflammatory reaction with infiltrates composed mainly of T cells and macrophages. Although myelin sheaths are the primary target of tissue destruction, axons, nerve cells and astrocytes are also affected, although to a lesser degree. Active lesions,
Is Th1-mediated autoimmunity against myelin the cause of inflammation in MS?
The pathology of inflammation in MS lesions is consistent with a T-cell-mediated immune reaction, leading to the recruitment of hematogenous macrophages and activation of microglia 4. This is similar to the pathology of experimental autoimmune encephalomyelitis (EAE), a disease induced by immunization of animals with CNS tissue, myelin or myelin proteins. Several features of MS lesions suggest that, as in EAE, the inflammatory process in MS is driven by a Th1-mediated autoimmune response. For
Additional demyelinating amplification factors are required to form demyelinated plaques
In most vertebrates, including rats, guinea pigs and primates, pure T-cell-mediated inflammation of the brain does not lead to demyelination. An exception to this is the mouse, in which extensive activation of macrophages and microglia in EAE, or in certain transgenic models, is associated with primary destruction of myelin. In these mouse models, signaling through TNF receptor 1 is required for the destruction of myelin and oligodendrocytes 13.
Pure inflammatory T-cell-mediated
Heterogenous patterns of demyelination in MS
A major restriction of pathogenetic studies of MS is the limited material available from actively demyelinating lesions, and it has required a large international effort to collect sufficient specimens to perform such a study 19, 20 (Box 1). A detailed immunopathological investigation of this material has revealed a profound heterogeneity in the patterns of demyelination between different patients, although active plaques from the same patient were very similar. All actively demyelinating
Axonal injury and loss: a consequence of inflammatory demyelination
Early descriptions of the pathology of MS, published in the early 1900s, emphasized the functional importance of axonal destruction in the lesions, which led to secondary (Wallerian) tract degeneration and brain atrophy 3. This aspect of MS pathology has received increased attention recently, as serial magnetic resonance imaging (MRI) investigations indicate that axonal loss within the lesions and brain atrophy correlate with permanent, progressive functional deficits. Axonal injury in MS
Is inflammation in MS lesions always deleterious?
As previously discussed, T-cell-mediated inflammation is the apparent driving force behind the pathological process in MS lesions. More recent data, however, indicate that inflammation might also be neuroprotective, or have a role in the repair of damaged tissue within the CNS. For example, autoimmune T cells protect neurons in the optic nerve from secondary degeneration after injury by partial crushing 30. The presence of macrophages stimulates remyelination in organ culture 31, an observation
Clinical identification of subgroups of MS patients
The heterogenous patterns of demyelination in individuals with MS patients are defined by the pathology of active lesions. However, we expect that clinical diagnosis and therapy would be aided by developing clinical and paraclinical markers to identify patient subgroups according to their pathogenetic pathways of lesion formation. As the association between clinical forms of the disease and pathological subtypes is limited, this approach will largely depend upon the development of suitable
Consequences of MS therapy
Demyelination in MS develops by a T-cell-driven inflammatory process. Thus, the primary nature of inflammation is undisputed and will remain central for treatments that modulate the immune system 8. There are, however, several aspects that limit the therapeutic efficacy of strategies directed exclusively against the inflammatory component of the disease. Currently, immune suppression is unable to stop the inflammatory reaction in the CNS and immune modulatory regimes using interferon β or
Outstanding questions
- •
What immunological and neurobiological mechanisms underlie the heterogenous patterns of MS pathology?
- •
Which are the most suitable clinical and paraclinical markers to define patient subgroups with different pathogenetic pathways in the formation of demyelinated plaques?
- •
Do patients with different pathogenetic pathways of demyelination require subtype-specific therapy?
- •
Are recent therapies developed against specific mechanisms of demyelination or axonal injury effective in MS patients?
Acknowledgements
These projects were funded by grants of the Bundesministerium für Bildung, Wissenschaft und Kunst (GZ 70.056/2-Pr/4/99), the Gemeinnützige Hertie Stiftung (GHS 2/540/99) and the US Multiple Sclerosis Society (RG 3051-A-1).
Glossary
- Primary demyelination
- destruction of myelin sheaths with relative sparing of axons.
- T helper 1 cells (Th1)
- MHC class II-restricted T cells that secrete a spectrum of cytokines including interleukin 2, interferon γ and lymphotoxin α, and elicit a delayed-type hypersensitivity reaction.
- T helper 2 cells (Th2)
- MHC class II-restricted T cells that secrete mainly interleukins 4, 5, and 6. They stimulate antibody production and are involved in allergic reactions.
- Class I-restricted cytotoxic T cells (Tc1)
References (37)
Clonal expansion of CD8 Tcells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction
J. Exp. Med.
(2000)Bacterial vaccines for the treatment of multiple sclerosis and other autoimmune diseases
Immunol. Today
(2000)Multiple sclerosis: Fas signaling in oligodendrocyte death
J. Exp. Med.
(1996)A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 117 cases
Brain
(1999)Temporary axonal conduction block and axonal loss in inflammatory neurological disease. A potential role for nitric oxide?
Ann. New York Acad. Sci.
(1999)Macrophages in CNS remyelination: friends or foe?
Neurochem. Res.
(1998)Activated human T cells, B cells and monocytes produce brain-derived neurotrophic factor (BDNF) in vitro and in brain lesions: A neuroprotective role of inflammation?
J. Exp. Med.
(1999)Multiple sclerosis pathology
The neuropathology of multiple sclerosis
- et al.
Axonal pathology in multiple sclerosis: a historical note
Brain Pathol.
(1999)
Immunology of multiple sclerosis
Proinflammatory and antiinflammatory cytokines in multiple sclerosis and central nervous system acquired immuno-deficiency syndrome
J. Immunother.
Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients
J.Clin. Invest.
The genetics of multiple sclerosis. A review
Biomed. Pharmacother.
Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems and perspectives
Brain
Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis
J. Neurol. Sci.
Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease
J. Exp. Med.
TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease
Brain
Cited by (550)
Role of omega-3 endocannabinoids in the modulation of T-cell activity in a multiple sclerosis experimental autoimmune encephalomyelitis (EAE) model
2023, Journal of Biological ChemistryMultiple sclerosis and neuromyelitis optica spectrum disorders
2022, Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders, Second EditionPleiotrophin Serum Level is Increased in Relapsing-Remitting Multiple Sclerosis and Correlates With Sex, BMI and Treatment
2022, Archives of Medical ResearchRole of fenofibrate in multiple sclerosis
2024, European Journal of Medical ResearchPotential Metabolite Biomarkers of Multiple Sclerosis from Multiple Biofluids
2024, ACS Chemical Neuroscience